Y. Liaw and C. Chu, Hepatitis B virus infection, The Lancet, vol.373, pp.582-592, 2009.

J. W. Park, K. M. Kwak, S. E. Kim, M. K. Jang, K. T. Suk et al., Comparison of the long-term efficacy between entecavir and tenofovir in treatment-naïve chronic hepatitis B patients, BMC Gastroenterol, vol.17, p.39, 2017.

Y. Xu, Y. Zhang, X. Wang, W. Qi, S. Qin et al., Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis, World J Gastroenterol WJG, vol.21, pp.7869-7876, 2015.

, HBV strain with mutations conferring resistance to both lamivudine and adefovir

, Hepatol Baltim Md, vol.41, pp.1391-1398

D. R. Langley, A. W. Walsh, C. J. Baldick, B. J. Eggers, R. E. Rose et al., Inhibition of Hepatitis B Virus Polymerase by Entecavir, J Virol, vol.81, pp.3992-4001, 2007.

A. Geipel, P. L. Seiz, H. Niekamp, M. Neumann-fraune, K. Zhang et al., Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine, Antivir Ther, vol.20, pp.779-787, 2015.

N. Yamada, R. Sugiyama, S. Nitta, A. Murayama, M. Kobayashi et al., Resistance mutations of hepatitis B virus in entecavir-refractory patients, Hepatol Commun, vol.1, pp.110-121, 2017.

Y. Liu, Y. Zhou, X. Li, M. Niu, R. Chen et al., Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice, Emerg Microbes Infect, vol.8, pp.354-365, 2019.

S. Hayashi, S. Murakami, K. Omagari, T. Matsui, E. Iio et al., Characterization of novel entecavir resistance mutations, J Hepatol, vol.63, pp.546-553, 2015.

X. Guo, J. Wu, F. Wei, Y. Ouyang, Q. Li et al., Trends in Hepatitis B Virus Resistance to Nucleoside/Nucleotide Analogs in North China from 2009 to 2016: A Retrospective Study, Int J Antimicrob Agents, vol.0, 2018.

. Man-ra-de, L. Wolters, F. Nevens, D. Chua, M. Sherman et al., Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection, Hepatology, vol.34, pp.578-582, 2001.

M. Osborn, Safety and efficacy of entecavir for the treatment of chronic hepatitis B, Infect Drug Resist, vol.4, pp.55-64, 2011.

T. Chang, R. G. Gish, S. J. Hadziyannis, J. Cianciara, M. Rizzetto et al., A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients, Gastroenterology, vol.129, pp.1198-1209, 2005.

X. Deng, Q. Li, and J. Guo, Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy, Virus Genes, vol.47, pp.1-9, 2013.

D. J. Tenney, R. E. Rose, C. J. Baldick, K. A. Pokornowski, B. J. Eggers et al., Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy, Hepatology, vol.49, pp.1503-1514, 2009.

J. Villeneuve, D. Durantel, S. Durantel, C. Westland, S. Xiong et al., Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient, J Hepatol, vol.39, pp.1085-1089, 2003.

M. Neumann-fraune, B. Beggel, R. Kaiser, and M. Obermeier, Hepatitis B Virus Drug Resistance Tools: One Sequence, Two Predictions, Intervirology, vol.57, pp.232-236, 2014.

T. F. Liu and R. W. Shafer, Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation, Clin Infect Dis, vol.42, pp.1608-1618, 2006.

H. Yoshitsugu, T. Sakurai, H. Ishikawa, A. Roy, M. Bifano et al., Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients, Diagn Microbiol Infect Dis, vol.70, pp.91-100, 2011.

M. Blanchet and C. Sureau, Analysis of the Cytosolic Domains of the Hepatitis B Virus Envelope Proteins for Their Function in Viral Particle Assembly and Infectivity, J Virol, vol.80, pp.11935-11945, 2006.

Y. Liu and K. M. Kitrinos, In Vitro Phenotyping of Recombinant Hepatitis B Virus Containing the Polymerase/Reverse Transcriptase Gene from Clinical IsolatesAntiviral Methods and Protocols, 2013.

H. Nakabayashi, K. Taketa, K. Miyano, T. Yamane, and J. Sato, Growth of human hepatoma cell lines with differentiated functions in chemically defined medium, Cancer Res, vol.42, pp.3858-3863, 1982.

D. J. Tenney, S. M. Levine, R. E. Rose, A. W. Walsh, S. P. Weinheimer et al., Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine, Antimicrob Agents Chemother, vol.48, pp.3498-3507, 2004.

J. Hu, J. Cui, J. Guo, W. Zhang, X. Cai et al., Phenotypic assay of a hepatitis B virus strain carrying an rtS246T variant using a new strategy, J Med Virol, vol.84, pp.34-43, 2012.

C. J. Baldick, D. J. Tenney, C. E. Mazzucco, B. J. Eggers, R. E. Rose et al., Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance, Hepatology, vol.47, pp.1473-1482, 2008.